Corcept Therapeutics Incorporated (CORT) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Total Assets Chart for Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) total assets for FY2025 were USD 836.7M, a -0.5% change from FY2024. Corcept Therapeutics Incorporated's total assets grew from USD 1.0M in 2000 to USD 836.7M in 2025 (79885.8% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 7.9%, 10-year CAGR of 32.0%, 20-year CAGR of 18.1%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $12.93B
- Implied Share Price
- $119.57
- Enterprise Value
- $11.89B
- Revenue (TTM)
- $830.81M
- EBITDA
- $8.08M
- Profit Margin
- 6.64%
- Trailing P/E
- 271.75
- Forward P/E
- 19.30
- Price/Book (MRQ)
- 18.00
- Price/Sales (TTM)
- 15.56
- EV/EBITDA
- 1405.48
- EV/Revenue
- 14.93
- Dividend Yield
- —
- Book Value
- $6.54
- Free Cash Flow (FY2025)
- $141.78M
- Free Cash Flow Yield
- 1.10%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.